LGL Group (NYSEAMERICAN:LGL) Share Price Passes Above Two Hundred Day Moving Average – Time to Sell?

LGL Group, Inc. (The) (NYSEAMERICAN:LGL)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $6.48 and traded as high as $7.38. LGL Group shares last traded at $7.26, with a volume of 2,083 shares changing hands.

LGL Group Stock Down 3.1%

The company has a 50 day simple moving average of $7.11 and a 200 day simple moving average of $6.48. The company has a market capitalization of $47.41 million, a price-to-earnings ratio of 42.71 and a beta of 0.31.

Insider Buying and Selling at LGL Group

In other LGL Group news, major shareholder Mario J. Gabelli bought 95,387 shares of LGL Group stock in a transaction that occurred on Tuesday, December 30th. The shares were acquired at an average price of $4.75 per share, for a total transaction of $453,088.25. Following the acquisition, the insider owned 572,324 shares of the company’s stock, valued at $2,718,539. The trade was a 20.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 18.90% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in LGL Group stock. Citadel Advisors LLC bought a new position in shares of LGL Group, Inc. (The) (NYSEAMERICAN:LGL) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 13,515 shares of the industrial products company’s stock, valued at approximately $90,000. Citadel Advisors LLC owned approximately 0.25% of LGL Group at the end of the most recent quarter. Hedge funds and other institutional investors own 30.28% of the company’s stock.

LGL Group Company Profile

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.